Real World Evidence ManagerAstraZeneca, Medical and Scientific Affairs, Biopharmaceuticals Medical, London, UKLondon, England, United Kingdom
OC 53.1 - Risk factors for Major Bleeding in Patients Anticoagulated with Factor Xa Inhibitors (FXai): An English Observational Study in the UK Clinical setting (AXIOM UK)
Tuesday, June 25, 202409:30 – 09:45 ICT
PB0984 - The Incidence of Major Bleeding and Case Fatality Rates in Patients Anticoagulated with Factor Xa Inhibitors: An Observational Study in the UK Clinical Setting (AXIOM UK)
Tuesday, June 25, 202413:45 – 14:45 ICT
